The Individual Effect of Surfactants on The Penetration of Glimepiride Transdermal Patches Using Dibutylpthalate as a Plasticizer
Glimepiride is an anti-diabetic drug with shorter half-life of 5 hrs. Glimepiride penetration into skin is difficulty. To study effects the penetration of glimepiride using different surfactants using dibutylpthalate.
Glimepiride transdermal Patches are prepared by using solvent casting method. Eudragit E -100, Polysorbate 80, Polysorbate 60 are used as a penetration enhancers. Dibutylpthalate acts as a plasticizer for the penetration enhancement.
The present study was to formulate and evaluate transdermal drug delivery system of Glimepiride. Results were evaluated for Thickness, Tensile strength, Folding endurance, and Drug content and In vitro penetration study was performed by using Franz diffusion cell. The drug content in transdermal patch F-1 shows 98,F-2 shows 93, F-3 shows 92.the drug permeation through matrix membrane shows good release with Eudragit E-100 copolymer and surfactant SLS. In comparison with three surfactants SLS gives good release for glimepiride with Eudragit E-100 matrix membrane.
From the results glimepiride with SLS anionic surfactant shows good penetration. Dibutylpthalate acts a plasticizer which improves the penetration of glimepiride.
2. Arora P et al., (2002); Design, development, physicochemical, and in-vitro and in-vivo Evaluation of transdermal patches containing diclofenac diethyl ammonium salt; J Pharm Sci ; 91(9); 2076-2089.
3. Aulton ME(2002); Pharmaceutics -The science of dosage form design; 2nd Ed. P (US): Churchill Livingstone
4. Chien YW (1987); Transdermal therapeutic system. In: Robinson, JR, Lee VHL. Eds. Controlled Drug Delivery Fundamentals and Applications 2nd Ed. New York: Marcel Dekker, Inc. ; 524-552.
5. Devi VK et al., (2003); Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride; Drug Dev. Ind. Pharm; 29(5); 495–503
6. Fulmer AW et al., (1986); Corneum lipid abnormalities in surfactant induced dry scaly skin; J Invest Dermatol; 86(5); 598–602.
7. Gloxhuber C et al., (1992); Surfactant science series. 2nd Ed. New York: Marcel Dekker; Anionic surfactants: Biochemistry, toxicology, dermatology.
8. Hardainiyan, S., K. Kumar, B. C. Nandy, and R. Saxena.(2017); Design, Formulation And In Vitro Drug Release From Transdermal Patches Containing Imipramine Hydrochloride As Model Drug”. IJPPSC; 9(6); 220-5
9. Lee CK et al., (1994); Skin permeability of various drugs with different lipophilicity. J Pharm Sci ; 83(4); 562–65.
10. Misra AN. Controlled and Novel Drug Delivery. In: N.K. Jain (Eds.), Transdermal Drug Delivery New Delhi, India: CBS Publisher and Distributor. 1997. 100-101.
11. Rajab, N. A., A. A. A. Rassol, S. M. Assaf, and A.- sayed A. Sallam. (2014) ; Preparation and evaluation of fentanyl transdremal patches using lidocaine as a model drug and azelaic acid as a penetration enhancer; International Journal of Pharmacy and Pharmaceutical Sciences; 6(7); 615-20
12. Reiger MM et al., 1997. Surfactant in Cosmetics. Vol. 68. New York: Marcel Dekker; 1997
13. Rhein LD et al., 1986. Surfactant structure effects on swelling of isolated human stratum corneum. J Soc Cosmet Chem. 1986; 37:125–39.
14. Swarbrick J. Encyclopedia of pharmaceutical technology. Surfactants in pharmaceutical products and systems.3rd ed. Vol. 6. Informa Healthcare, CRC press hardcover; 2006.
15. Walters KA et al., 1988. Non-ionic surfactant effects on hairless mouse skin permeability characteristics. J Pharm Pharmacol. 1988; 40:525–29.